Parental infant jaundice colour card design successfully validated by comparing it with total serum bilirubin.

AIM: We designed a jaundice colour card that could be used by the parents of neonates and validated it by comparing it with total serum bilirubin levels. METHODS: There were 106 term Chinese neonates in the study. The majority weighed between 2500 g and 3499 g (63%) and had a gestational age of 37-40 weeks (77%). The jaundice colour card and photometric determination were used to screen for neonatal jaundice and compared with serum bilirubin. RESULTS: The bilirubin levels were measured by mothers using the jaundice colour card, and 67% of the measurements were taken at 11-20 days (range 3-30). The measurements at the infant's forehead, cheek and sternum showed strong correlations with total serum bilirubin. The mean differences between the total serum bilirubin and the jaundice colour card measurements from the forehead, cheek and sternum were 1.9 mg/dL, 0.3 mg/dL and 1.5 mg/dL, respectively. When total serum bilirubin >13 mg/dL was used as the cut-off point, the areas under the receiver operating characteristics curves were 0.934 for the forehead, 0.985 for the cheek and 0.966 for the sternum. CONCLUSION: We established the validity of the jaundice colour card as a parental measurement tool for jaundice in Chinese neonates, and the cheek was the best measurement site.

[Astragalus Granule Combined Auricular Point Sticking for Cough Variant Asthma in Children].

Objective To observe the clinical efficacy and effect of Astragalus Granule (AG) , auricular point sticking combined with aerosol inhalation on the levels of tumor necrosis factor-α (TNF- a), interleukin-4 (IL-4), interleukin-10 (IL-10), eosinophil cell count (EOS), and immunoglobulin E (IgE) in cough variant asthma (CVA) children. Methods Totally 150 CVA children patients were ran- domly assigned to three group, the Western medicine group (WM) , the Chinese medicine group (CM) , and the combined group, 50 in each group. All patients received basic treatment of aerosol inhalation with Budesonide suspension and Terbutaline Sulphate Solution. Patients in the WM group received basic treatment alone. Those in the CM group additionally took AG. Those in the combined group additionally took AG and received auricular point sticking. The therapeutic course for all was 8 weeks. Expression levels of TNF-α, IL-4, and IL-10 were detected in each group using ELISA before and after treatment. Levels of EOS and IgE were detected using hematology analyzer. Results Compared with before treatment in the same group, the expression levels of TNF-α and IgE decreased in the WM group after treatment (P < 0. 05) ; the expression levels of TNF-α, IL-4, EOS, and IgE decreased, but the level of IL-10 increased in the CM group and the combined group after treatment (P <0. 05). Compared with the WM group at the same time, the expression level of IL-10 increased, and the level of IgE decreased in the CM group (P < 0. 05). The control rate, the markedly effective rate, and the total effective rate were elevated (P < 0. 05), and the ineffective rate was lowered (P <0. 05) in the CM group. In the combined group the expression levels of TNF-α, IL-4, EOS, and IgE decreased, and the level of IL-10 increased after treatment (P <0. 05). The cough alleviation time and the disappearance time were shortened in the combined group after treatment (P <0. 05). The control rate, the markedly effective rate, and the total effective rate were elevated (P <0. 05), and the ineffective rate was lowered (P <0. 05) in the combined group after treatment. Compared with the CM group at the same time point, the expression level of IL-10 increased (P < 0. 05), the levels of IgE and EOS were lowered (P <0. 05), the cough alleviation time and the disappear- ance time were shortened (P <0. 05) , the control rate and the total effective rate were elevated in the combined group after treatment (P <0. 05). Conclusion AG, auricular point sticking combined with aerosol inhalation could significantly reduce the levels of TNF-α, IL-4, EOS, and IgE, and improve the level of IL-10 in CVA children patients, with significant clinical effects.